PropThink: TH-302 Development: In the Shadow of the Competition

[ACN Newswire] – By Jake KingAfter declines in the first half of the week, shares of Threshold Pharmaceuticals (NASDAQ:THLD) rebounded on Thursday morning following an update on the company’s ongoing Phase 2 trial of TH-302 … more

View todays social media effects on THLD

View the latest stocks trending across Twitter. Click to view dashboard